$206.28▾ 0.17%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$3.45cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
98th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
+3.4%year over year
Watch
Revenue growth has flattened.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Biogen Inc. turns 345¢ of every reported profit-dollar into real cash. Revenue growth has flattened. Its valuation sits in the richer end of its own recent range. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$5.63
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin8.3%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$10.03B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days5 articles
4 bullish1 neutral0 bearish
Biogen Completes Acquisition of RayThera Inc.
Why Supernus Pharmaceuticals Stock Topped the Market Today
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
Why Biogen Stock Topped the Market TodayAutoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.